Protagonist Therapeutics, Inc (PTGX) stock
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics, Inc grew revenue 34.8% to $281.99M over the twelve months to Jun 30, 2026. Operating income rose 143.3% to $58.34M, moving the operating margin from 11.5% to 20.7%. Free cash flow was $130.58M, up 252.0% from a year earlier. At the latest close the market valued the company at $8.07B, 121.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.07B
- P/E ratio
- 121.0
- Price to sales
- 28.61
- Price to book
- 9.59
- Dividend yield
- –
- Free cash flow yield
- 1.62%
Fundamentals
- Revenue
- $281.99M
- Net income
- $82.91M
- EPS, diluted
- $1.03
- Free cash flow
- $130.58M
- Book value per share
- $11.85
- Diluted shares
- 71M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $124.83
- Open
- $124.65
- Day's range
- $121.75 – $125.90
- Volume
- 583,078
- Average volume (20 days)
- 593,761
- Index membership
- S&P SmallCap 600 (since Aug 2024), Russell 2000, Russell 3000
- 52-week range
- $77.00 – $160.81
- RSI (14 days)
- 32.5
- Volatility (1 year)
- 40.3%
- Relative volume
- 0.93×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTGX | S&P 500 | Difference | PTGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.2% | -4.0% | +0.9 pts | ||
| 3 months | -21.4% | -5.0% | −16.4 pts | ||
| Year to date | +42.7% | +8.2% | +34.5 pts | ||
| 1 year | +47.1% | +11.2% | +35.9 pts | ||
| 3 years | +641.6% | +68.5% | +573.2 pts | +95.0% | +19.0% |
| 5 years | +242.3% | +67.3% | +175.0 pts | +27.9% | +10.8% |
| 10 years | +398.9% | +291.6% | +107.2 pts | +17.4% | +14.6% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Protagonist Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Protagonist Therapeutics
Pharmaceutical Preparations
Protagonist Therapeutics is an integrated biopharmaceutical company focused on discovering and developing differentiated peptide-based medicines. The company organizes its research across three core therapeutic segments: inflammation and immunology, hematology, and metabolic diseases. Key development-stage assets include icotrokinra for plaque psoriasis, rusfertide for polycythemia vera, and preclinical candidates targeting obesity and related conditions. Operating primarily through strategic partnerships, Protagonist collaborates with major multinational pharmaceutical corporations such as Janssen Biotech and Takeda Pharmaceuticals for Phase 2 and Phase 3 development, regulatory submissions, and commercialization.
Company profile, executives and historyProtagonist Therapeutics stock: common questions
What is Protagonist Therapeutics's stock price?
PTGX closed at $124.67 on Nov 17, 2026, down 0.13% on the day. Over the past 52 weeks it traded between $77.00 and $160.81.
What is Protagonist Therapeutics's market cap?
Protagonist Therapeutics was worth $8.07B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is PTGX's P/E ratio?
PTGX trades at 121.0 times earnings, based on diluted earnings per share of $1.03 over the twelve months to Jun 30, 2026.
How much revenue does Protagonist Therapeutics make?
Protagonist Therapeutics reported revenue of $281.99M for the twelve months to Jun 30, 2026, up 34.8% from a year earlier.
Does Protagonist Therapeutics pay a dividend?
No. Protagonist Therapeutics has not paid a cash dividend over the last twelve months.
When does Protagonist Therapeutics report earnings next?
Protagonist Therapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PTGX stock performed over the past year?
Including dividends, PTGX returned +47.1% over the past year, against +11.2% for the S&P 500.
How many PTGX shares are sold short?
10M shares were sold short at the latest FINRA report, 16.09% of the float, or 16.9 days of average trading volume.
Who are Protagonist Therapeutics's competitors?
Companies most similar to Protagonist Therapeutics by business, industry and size include NRIX, EVO, RARE, HCM, AAPG.
See a number that looks wrong?